GlassScriptPhysician profile
Steven Nadler
NPI 1710982210
$4,192.71
in general payments reported to CMS, 2019-2025
24 companies · $883 in 2025
The $883 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $239 · 2021: $494 · 2022: $512 · 2023: $427 · 2024: $918 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $809.03 | 2019-2025 | |
| Janssen Biotech, INC. | $669.17 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $540.67 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $499.15 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $448.38 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $183.85 | 2023-2025 | Sucraid, Sucraid |
| Celgene Corporation | $179.23 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $159.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Ethicon US, LLC | $121.84 | 2021 | |
| Genzyme Corporation | $110.58 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $88.63 | 2019-2023 | Dificid |
| Aimmune Therapeutics, INC. | $50.17 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $41.66 | 2024-2025 | Bylvay, Iqirvo |
| Intercept Pharmaceuticals, INC. | $40.57 | 2019-2024 | |
| Allergan, INC. | $38.01 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $36.38 | 2019-2022 | |
| Novo Nordisk INC | $35.64 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $32.38 | 2025 | Voquezna |
| Alfasigma USA, INC. | $30.84 | 2020 | |
| Ardelyx, INC. | $18.82 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $18.12 | 2024 | Dupixent |
| Shionogi INC | $14.04 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.12 | 2022 | |
| Daiichi Sankyo INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Nadler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.